An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma

References

• American Cancer Society. Cancer Facts; Figures. Atlanta, GA: American Cancer Society; 2019. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html.
   Google Scholar
• Ak Cj E-N, Grandis JR, Takata T, et al. WHO Classification of Head and Neck Tumours: 4th edition.. Lyon: International Agency for Research on Cancer; 2017.
   Google Scholar
• Chow LQM, Longo DL. Head and neck cancer. N Engl J Med. 2020 Jan 2;382(1):60–72.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Giraldi L, Leoncini E, Pastorino R, et al. Alcohol and cigarette consumption predict mortality in patients with head and neck cancer: a pooled analysis within the international head and neck cancer epidemiology (INHANCE) consortium. Ann Oncol. 2017 Nov 1;28(11):2843–2851.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Sougnez C, Lichtenstein L, et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 [2015 January 01];517(7536):576–582.
   PubMed Web of Science ®Google Scholar
• Wang Q, Shi YL, Zhou K, et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 2018 Jul 3;9(7):739.
   PubMed Web of Science ®Google Scholar
• Holmes D. PI3K pathway inhibitors approach junction.Nat Rev Drug Discov. 2011 [2011 August 01];10(8):563–564.
   PubMed Web of Science ®Google Scholar
• Jung K, Kang H, Mehra R. Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). Cancers Head Neck. 2018;3:3.
   PubMedGoogle Scholar
• Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol. 1999 Apr;11(2):219–225.
   PubMed Web of Science ®Google Scholar
• Yoshioka K, Yoshida K, Cui H, et al. Endothelial PI3K-C2alpha, a class II PI3K, has an essential role in angiogenesis and vascular barrier function. Nat Med. 2012 Oct;18(10):1560–1569.
   PubMed Web of Science ®Google Scholar
• Backer JM. The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J. 2008 Feb 15;410(1):1–17.
   PubMed Web of Science ®Google Scholar
• Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013 Jul;3(7):761–769. .
   PubMed Web of Science ®Google Scholar
• Qiu W, Schonleben F, Li X, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 2006 Mar 1;12(5):1441–1446.
   PubMed Web of Science ®Google Scholar
• Nichols AC, Palma DA, Chow W, et al. High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2013 Jun;139(6):617–622. .
   PubMed Web of Science ®Google Scholar
• Koncar RF, Feldman R, Bahassi EM, et al. Comparative molecular profiling of HPV-induced squamous cell carcinomas. Cancer Med. 2017 Jul;6(7):1673–1685.
   PubMed Web of Science ®Google Scholar
• Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 2015 Jan;12(1):11–26.
   PubMed Web of Science ®Google Scholar
• Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019 May 16;380(20):1929–1940.
   PubMed Web of Science ®Google Scholar
• Dunn LA, Riaz N, Fury MG, et al. A phase 1b study of Cetuximab and BYL719 (Alpelisib) concurrent with intensity modulated radiation therapy in stage III-IVB head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):564–570.
   PubMed Web of Science ®Google Scholar
• Day D, Prawira A, Spreafico A, et al. Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck. Oral Oncol. 2020 May;25(108):104753.
   Google Scholar
• Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017 Sep 1;28(9):2169–2178.
   PubMed Web of Science ®Google Scholar
• Pitz MW, Eisenhauer EA, MacNeil MV, et al. Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol. 2015 Sep;17(9):1270–1274.
   PubMed Web of Science ®Google Scholar
• Bowles DW, Kochenderfer M, Cohn A, et al. A randomized, phase II trial of Cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with metastatic colorectal carcinoma. Clin Colorectal Cancer. 2016 Dec;15(4):337–44 e2. .
   PubMed Web of Science ®Google Scholar
• Garlich JR, De P, Dey N, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 1;68(1):206–215.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem Compound Summary for CID 16654980. Buparlisib. [cited 2020 Oct 20]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Buparlisib
   Google Scholar
• Brachmann SM, Kleylein-Sohn J, Gaulis S, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012 Aug;11(8):1747–1757.
   PubMed Web of Science ®Google Scholar
• Bohnacker T, Prota AE, Beaufils F, et al. Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nat Commun. 2017 Mar 9;8:14683.
   PubMed Web of Science ®Google Scholar
• Maira SM, Pecchi S, Huang A, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012 Feb;11(2):317–328.
   PubMed Web of Science ®Google Scholar
• Koul D, Fu J, Shen R, et al. Antitumor activity of NVP-BKM120–a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res. 2012 Jan 1;18(1):184–195.
   PubMed Web of Science ®Google Scholar
• Keam B, Kim S, Ahn YO, et al. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015 Jan;35(1):175–182.
   PubMed Web of Science ®Google Scholar
• Mizrachi A, Shamay Y, Shah J, et al. Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. Nat Commun. 2017 Feb 13;8:14292.
   PubMed Web of Science ®Google Scholar
• Amornphimoltham P, Patel V, Sodhi A, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 2005 Nov 1;65(21):9953–9961.
   PubMed Web of Science ®Google Scholar
• Wirtz ED, Hoshino D, Maldonado AT, et al. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies. JAMA Otolaryngol Head Neck Surg. 2015 Jun;141(6):543–549.
   PubMed Web of Science ®Google Scholar
• Turke AB, Song Y, Costa C, et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012 Jul 1;72(13):3228–3237.
   PubMed Web of Science ®Google Scholar
• Borcoman E, De La Rochere P, Richer W, et al. Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. Oncoimmunology. 2019;8(5):e1581556.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen P, Chen Z, et al. 086 Buparlisib (AN2025) as a potential treatment for anti-PD-1 non-responding tumor. Radiotherapy&Oncology. 2019;132:45.
   Google Scholar
• Ando Y, Inada-Inoue M, Mitsuma A, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci. 2014 Mar;105(3):347–353.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012 Jan 20;30(3):282–290.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhang LI, Trandafir L, et al. Phase I Study of the Pan-PI3K inhibitor Buparlisib in adult Chinese patients with advanced solid tumors. Anticancer Res. 2016 Nov;36(11):6185–6194. .
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Harvey RD, Carthon B, et al. A phase I study of safety, pharmacokinetics, and pharmacodynamics of concurrent Everolimus and Buparlisib treatment in advanced solid tumors. Clin Cancer Res. 2020;26:2497–2505.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Snyder AE, Carvajal RD, et al. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015 Apr;75(4):747–755.
   PubMed Web of Science ®Google Scholar
• Smyth LM, Monson KR, Jhaveri K, et al. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Invest New Drugs. 2017 Dec;35(6):742–750.
   PubMed Web of Science ®Google Scholar
• Bedard PL, Tabernero J, Janku F, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015 Feb 15;21(4):730–738.
   PubMed Web of Science ®Google Scholar
• Bardia A, Gounder M, Rodon J, et al. Phase Ib study of combination therapy with MEK inhibitor Binimetinib and Phosphatidylinositol 3-Kinase inhibitor Buparlisib in patients with advanced solid tumors with RAS/RAF alterations. Oncologist. 2020 Jan;25(1):e160–e69. .
   PubMed Web of Science ®Google Scholar
• Lorch JH, Tishler RB, Chau NG, et al. A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN). J Clin Oncol. 2018;36(15_suppl): 6071–71. DOI:10.1200/JCO.2018.36.15_suppl.6071.
   Web of Science ®Google Scholar
• Soulieres D, Faivre S, Mesia R, et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017 Mar;18(3):323–335.
   PubMed Web of Science ®Google Scholar
• Soulieres D, Licitra L, Mesia R, et al. Molecular alterations and Buparlisib efficacy in patients with Squamous cell carcinoma of the head and neck: biomarker analysis from BERIL-1. Clin Cancer Res. 2018 Jun 1;24(11):2505–2516.
   PubMed Web of Science ®Google Scholar
• Kim HR, Kang HN, Yun MR, et al. Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN). J Clin Oncol. 2015;33(15_suppl): 6049–49. doi:10.1200/jco.2015.33.15_suppl.6049.
   Google Scholar
• Fayette J, Digue L, Ségura-Ferlay C, et al. Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial. Ann Oncol. 2019;30:v455.
   Web of Science ®Google Scholar
• Piha-Paul SA, Taylor MH, Spitz D, et al. Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. Oncotarget. 2019 Nov 5;10(60):6526–6535.
   PubMedGoogle Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375(19):1856–1867.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019 Jan 12;393(10167):156–167.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Nov 23;394(10212):1915–1928.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019 Jan 5;393(10166):40–50.
   PubMed Web of Science ®Google Scholar
• Nakauchi C, Kagara N, Shimazu K, et al. Detection of TP53/PIK3CA mutations in cell-free plasma DNA from metastatic breast cancer patients using next generation sequencing. Clin Breast Cancer. 2016 Oct;16(5):418–423.
   PubMed Web of Science ®Google Scholar
• Rodriguez BJ, Cordoba GD, Aranda AG, et al. Detection of TP53 and PIK3CA mutations in circulating tumor DNA using next-generation sequencing in the screening process for early breast cancer diagnosis. J Clin Med. 2019 Aug 7;8:8.
   Web of Science ®Google Scholar